Categories: Wire Stories

Alliance Pharma Opens State-of-the-Art Bioanalytical Laboratory in Brisbane

MALVERN, Pa.–(BUSINESS WIRE)–Alliance Pharma (Alliance), a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its new 20,000-square-foot (1,858-square-meter) bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia.


The new Australia facility, which the company announced plans for earlier this summer, includes an expansive lab to provide much-needed small and large molecule bioanalytical services for a region with limited choices for bioanalytical support.

�Alliance Pharma’s expanded presence in Australia affirms our commitment to combining scientific talent and technology to deliver global drug development solutions,” said Alliance CEO, Patrick Bennett. “In this new purpose-built laboratory, our talented teams will use their diverse experience and expertise to provide high-quality bioanalytical services.”

“Our new state-of-the-art science facility in Brisbane will further strengthen our global bioanalytical capabilities. It will allow biotech companies to work with us in Australia in the early phase and then transfer the knowledge on these assays to other regions to support the later development phases. Our objective is to accelerate the growth of our best-in-class portfolio and deliver industry-leading drug development service for our worldwide clients,” said Alliance Pharma Site President, Australia, Jason (Hao) Wang, Ph.D.

About Alliance Pharma

Founded in 2008, Alliance is a contract research organization (CRO) with bioanalytical, DMPK, and CMC testing labs in Malvern, PA, Brisbane, AU, Cambridge, U.K., and Sandwich, U.K. The labs specialize in advanced research services for all drug molecules, cell and gene therapies, and drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Alliance’s mission is to build a trusted partnership with our clients to support their successful drug development programs. Our business philosophy is based on a foundation of trust, professional ethics, scientific excellence, and regulatory compliance.

Contacts

John Ryan

Vice President of Commercial Operations

+1 609-273-6062

jryan@alliancepharmaco.com

Alex

Recent Posts

WNS Files Fiscal 2024 Annual Report on Form 20-F

NEW YORK, LONDON & MUMBAI--(BUSINESS WIRE)--$WNS #AnnualReport--WNS (Holdings) Limited (NYSE: WNS), a leading provider of…

1 day ago

Cleveland-Cliffs Applauds International Trade Commission’s Decision to Uphold Tariffs on Japanese Imports

CLEVELAND--(BUSINESS WIRE)--Cleveland-Cliffs Inc. (NYSE: CLF) today applauded the International Trade Commission’s (ITC) unanimous decision to…

1 day ago

Eze Perfumes: India’s Fragrance Footprint Expands to US!

NEW YORK--(BUSINESS WIRE)--#D2C--A year since its launch under Incredible Indriya, Eze Perfumes, the first direct-to-consumer…

1 day ago

Asia-Pacific Wind-Assisted Propulsion Market Analysis and Forecast, 2023-2032 Featuring Prominent Players – Eco Marine Power Co. Ltd and Mitsui O.S.K. Lines – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Wind-Assisted Propulsion Market: Focus on Application, Technology, Installation Type, Vessel Type, and…

1 day ago

YY Group Expands into Cambodian Hospitality and Hotel Industry

SINGAPORE, May 10, 2024 (GLOBE NEWSWIRE) -- YY Group Holding Limited (NASDAQ: YYGH) (“YY Group”,…

2 days ago

Wipro Appoints Vinay Firake as Chief Executive Officer for APMEA Strategic Market Unit

DUBAI, United Arab Emirates & BENGALURU, India--(BUSINESS WIRE)--$WIPRO #APMEA--Wipro Limited (NYSE: WIT, BSE: 507685, NSE:…

2 days ago